A multi-national phase III study of satraplatin plus prednisone or placebo plus prednisone in patients with hormone refractory prostate cancer previously treated with one cytotoxic chemotherapy regimen.

Trial Profile

A multi-national phase III study of satraplatin plus prednisone or placebo plus prednisone in patients with hormone refractory prostate cancer previously treated with one cytotoxic chemotherapy regimen.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Prednisone (Primary) ; Satraplatin (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SPARC
  • Sponsors Agennix AG
  • Most Recent Events

    • 30 Apr 2012 Company (Agennix AG) added as reported by ClinicalTrials.gov.
    • 05 Oct 2009 Results published in the Journal of Clinical Oncology.
    • 09 Mar 2009 Results of a subgroup analyses regarding a secondary endpoint were presented at the 2009 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top